Skip to main content
Top
Published in: Journal of Nephrology 1/2014

01-02-2014 | Original Article

Fibrate treatment of eEOCs in murine AKI

Authors: Daniel Patschan, Katrin Schwarze, Elvira Henze, Susann Patschan, Roman Scheidemann, Gerhard Anton Müller

Published in: Journal of Nephrology | Issue 1/2014

Login to get access

Abstract

Background

Early endothelial outgrowth cells (eEOCs) protect mice from acute kidney injury (AKI). Peroxisome proliferator-activated receptor-alpha (PPAR-α) has been shown to mediate renoprotective effects under different experimental conditions. The aim of the study was to investigate consequences of fibrate treatment of murine eEOCs in a cell-based therapeutic approach to AKI.

Methods

Male C57/Bl6N mice, subjected to unilateral renal ischemia (40 min) post-uninephrectomy, were systemically injected with 0.5 × 106 untreated or fenofibrate (FF 1, 5, 10 or 50 μm)/clofibrate (CF 1 mm) pretreated syngeneic murine eEOCs. Renal function and morphology were analyzed 48 h later. Cellular consequences of eEOC treatment with fibrates (FF 1, 5, 10, 50 μm, CF 1 mm) were evaluated using different in vitro assays (direct cell migration, apoptosis/necrosis, ELISA studies).

Results

Administration of untreated eEOCs did not protect mice from AKI. Injection of eEOCs treated with CF (1 mm) or FF 50 μm did not result in any protection from ischemia-induced renal dysfunction. In vitro analysis showed reduced cellular secretion of vasoprotective vascular endothelial growth factor (VEGF), an effect that was more pronounced with CF; FF increased percentages of apoptotic/necrotic eEOCs, and both substances failed to stimulate migration of cultured cells. With lower FF concentrations (1, 5, 10 μm) cell survival was increased and 10 μm FF stimulated VEGF secretion. In vivo administration of FF-treated eEOCs (10 μm) also did not result in any renoprotective effect.

Conclusion

PPAR-α activation using fibrates does not stimulate renoprotective effects of syngeneic murine eEOCs in ischemic AKI, although lower fibrate concentrations significantly activate eEOCs in vitro.
Literature
1.
go back to reference Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T et al (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science (New York, NY) 275(5302):964–967CrossRef Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T et al (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science (New York, NY) 275(5302):964–967CrossRef
2.
go back to reference Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR et al (2007) Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 35(7):1109–1118PubMedCrossRef Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR et al (2007) Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 35(7):1109–1118PubMedCrossRef
3.
go back to reference Yoder MC, Ingram DA (2009) The definition of EPCs and other bone marrow cells contributing to neoangiogenesis and tumor growth: is there common ground for understanding the roles of numerous marrow-derived cells in the neoangiogenic process? Biochim Biophys Acta 1796(1):50–54PubMedCentralPubMed Yoder MC, Ingram DA (2009) The definition of EPCs and other bone marrow cells contributing to neoangiogenesis and tumor growth: is there common ground for understanding the roles of numerous marrow-derived cells in the neoangiogenic process? Biochim Biophys Acta 1796(1):50–54PubMedCentralPubMed
4.
go back to reference Patschan D, Hildebrandt A, Rinneburger J, Wessels JT, Patschan SA, Becker JU et al (2012) The hormone Melatonin stimulates renoprotective effects of early outgrowth endothelial progenitor cells in acute ischemic kidney injury. Am J Physiol Renal Physiol. Epub 2012/02/24 Patschan D, Hildebrandt A, Rinneburger J, Wessels JT, Patschan SA, Becker JU et al (2012) The hormone Melatonin stimulates renoprotective effects of early outgrowth endothelial progenitor cells in acute ischemic kidney injury. Am J Physiol Renal Physiol. Epub 2012/02/24
5.
go back to reference Patschan D, Krupincza K, Patschan S, Zhang Z, Hamby C, Goligorsky MS (2006) Dynamics of mobilization and homing of endothelial progenitor cells after acute renal ischemia: modulation by ischemic preconditioning. Am J Physiol Renal Physiol 291(1):F176–F185PubMedCrossRef Patschan D, Krupincza K, Patschan S, Zhang Z, Hamby C, Goligorsky MS (2006) Dynamics of mobilization and homing of endothelial progenitor cells after acute renal ischemia: modulation by ischemic preconditioning. Am J Physiol Renal Physiol 291(1):F176–F185PubMedCrossRef
6.
go back to reference Patschan D, Patschan S, Gobe GG, Chintala S, Goligorsky MS (2007) Uric acid heralds ischemic tissue injury to mobilize endothelial progenitor cells. JASN 18(5):1516–1524PubMedCrossRef Patschan D, Patschan S, Gobe GG, Chintala S, Goligorsky MS (2007) Uric acid heralds ischemic tissue injury to mobilize endothelial progenitor cells. JASN 18(5):1516–1524PubMedCrossRef
7.
go back to reference Patschan D, Patschan S, Muller GA (2011) Endothelial progenitor cells in acute ischemic kidney injury: strategies for increasing the cells’ renoprotective competence. Int J Nephrol 2011:828369PubMedCentralPubMed Patschan D, Patschan S, Muller GA (2011) Endothelial progenitor cells in acute ischemic kidney injury: strategies for increasing the cells’ renoprotective competence. Int J Nephrol 2011:828369PubMedCentralPubMed
8.
go back to reference Patschan D, Patschan S, Wessels JT, Becker JU, David S, Henze E et al (2010) Epac-1 activator 8-O-cAMP augments renoprotective effects of syngeneic [corrected] murine EPCs in acute ischemic kidney injury. Am J Physiol Renal Physiol 298(1):F78–F85PubMedCrossRef Patschan D, Patschan S, Wessels JT, Becker JU, David S, Henze E et al (2010) Epac-1 activator 8-O-cAMP augments renoprotective effects of syngeneic [corrected] murine EPCs in acute ischemic kidney injury. Am J Physiol Renal Physiol 298(1):F78–F85PubMedCrossRef
9.
go back to reference Murohara T (2010) Cord blood-derived early outgrowth endothelial progenitor cells. Microvasc Res 79(3):174–177PubMedCrossRef Murohara T (2010) Cord blood-derived early outgrowth endothelial progenitor cells. Microvasc Res 79(3):174–177PubMedCrossRef
10.
go back to reference Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ et al (2006) International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58(4):726–741PubMedCrossRef Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ et al (2006) International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58(4):726–741PubMedCrossRef
11.
go back to reference Belfiore A, Genua M, Malaguarnera R (2009) PPAR-gamma agonists and their effects on IGF-I receptor signaling: implications for cancer. PPAR Res 2009:830501PubMedCentralPubMedCrossRef Belfiore A, Genua M, Malaguarnera R (2009) PPAR-gamma agonists and their effects on IGF-I receptor signaling: implications for cancer. PPAR Res 2009:830501PubMedCentralPubMedCrossRef
12.
go back to reference Wu L, Yan C, Czader M, Foreman O, Blum JS, Kapur R et al (2012) Inhibition of PPARgamma in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis. Blood 119(1):115–126PubMedCrossRef Wu L, Yan C, Czader M, Foreman O, Blum JS, Kapur R et al (2012) Inhibition of PPARgamma in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis. Blood 119(1):115–126PubMedCrossRef
13.
14.
go back to reference Balakumar P, Kadian S, Mahadevan N (2012) Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney? Pharmacol Res 65(4):430–436PubMedCrossRef Balakumar P, Kadian S, Mahadevan N (2012) Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney? Pharmacol Res 65(4):430–436PubMedCrossRef
15.
go back to reference Takahashi K, Kamijo Y, Hora K, Hashimoto K, Higuchi M, Nakajima T et al (2011) Pretreatment by low-dose fibrates protects against acute free fatty acid-induced renal tubule toxicity by counteracting PPARalpha deterioration. Toxicol Appl Pharmacol 252(3):237–249PubMedCrossRef Takahashi K, Kamijo Y, Hora K, Hashimoto K, Higuchi M, Nakajima T et al (2011) Pretreatment by low-dose fibrates protects against acute free fatty acid-induced renal tubule toxicity by counteracting PPARalpha deterioration. Toxicol Appl Pharmacol 252(3):237–249PubMedCrossRef
16.
go back to reference Tanaka Y, Kume S, Araki S, Isshiki K, Chin-Kanasaki M, Sakaguchi M et al (2011) Fenofibrate, a PPARalpha agonist, has renoprotective effects in mice by enhancing renal lipolysis. Kidney Int 79(8):871–882PubMedCrossRef Tanaka Y, Kume S, Araki S, Isshiki K, Chin-Kanasaki M, Sakaguchi M et al (2011) Fenofibrate, a PPARalpha agonist, has renoprotective effects in mice by enhancing renal lipolysis. Kidney Int 79(8):871–882PubMedCrossRef
17.
go back to reference Kidani Y, Bensinger SJ (2012) Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity. Immunol Rev 249(1):72–83PubMedCrossRef Kidani Y, Bensinger SJ (2012) Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity. Immunol Rev 249(1):72–83PubMedCrossRef
18.
go back to reference Sharifpanah F, Wartenberg M, Hannig M, Piper HM, Sauer H (2008) Peroxisome proliferator-activated receptor alpha agonists enhance cardiomyogenesis of mouse ES cells by utilization of a reactive oxygen species-dependent mechanism. Stem Cells 26(1):64–71PubMedCrossRef Sharifpanah F, Wartenberg M, Hannig M, Piper HM, Sauer H (2008) Peroxisome proliferator-activated receptor alpha agonists enhance cardiomyogenesis of mouse ES cells by utilization of a reactive oxygen species-dependent mechanism. Stem Cells 26(1):64–71PubMedCrossRef
19.
go back to reference Chawla A, Lazar MA (1994) Peroxisome proliferator and retinoid signaling pathways co-regulate preadipocyte phenotype and survival. Proc Natl Acad Sci USA 91(5):1786–1790PubMedCrossRef Chawla A, Lazar MA (1994) Peroxisome proliferator and retinoid signaling pathways co-regulate preadipocyte phenotype and survival. Proc Natl Acad Sci USA 91(5):1786–1790PubMedCrossRef
20.
go back to reference Smirnova IV, Kajstura M, Sawamura T, Goligorsky MS (2004) Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation. Am J Physiol Heart Circ Physiol 287(2):H782–H790PubMedCrossRef Smirnova IV, Kajstura M, Sawamura T, Goligorsky MS (2004) Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation. Am J Physiol Heart Circ Physiol 287(2):H782–H790PubMedCrossRef
21.
go back to reference Wilding JP (2012) PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. Diabetes Obes Metab. Epub 2012/03/27 Wilding JP (2012) PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. Diabetes Obes Metab. Epub 2012/03/27
22.
go back to reference Adedapo A, Oyekan A (2012) Effects of fenofibrate, a PPAR-alpha ligand, on the haemodynamics of glycerol-induced renal failure in rats. Hum Exp Toxicol. Epub 2012/08/04 Adedapo A, Oyekan A (2012) Effects of fenofibrate, a PPAR-alpha ligand, on the haemodynamics of glycerol-induced renal failure in rats. Hum Exp Toxicol. Epub 2012/08/04
23.
go back to reference Yakubu MA, Nsaif RH, Oyekan AO (2010) Regulation of cerebrovascular endothelial peroxisome proliferator activator receptor alpha expression and nitric oxide production by clofibrate. Bratisl Lek Listy 111(5):258–264PubMed Yakubu MA, Nsaif RH, Oyekan AO (2010) Regulation of cerebrovascular endothelial peroxisome proliferator activator receptor alpha expression and nitric oxide production by clofibrate. Bratisl Lek Listy 111(5):258–264PubMed
24.
go back to reference Liu J, Lu C, Li F, Wang H, He L, Hao Y et al (2011) PPAR-alpha agonist fenofibrate upregulates tetrahydrobiopterin level through increasing the expression of guanosine 5′-triphosphate cyclohydrolase-I in human umbilical vein endothelial cells. PPAR Res 2011:523520PubMedCentralPubMed Liu J, Lu C, Li F, Wang H, He L, Hao Y et al (2011) PPAR-alpha agonist fenofibrate upregulates tetrahydrobiopterin level through increasing the expression of guanosine 5′-triphosphate cyclohydrolase-I in human umbilical vein endothelial cells. PPAR Res 2011:523520PubMedCentralPubMed
25.
go back to reference Carmona G, Chavakis E, Koehl U, Zeiher AM, Dimmeler S (2008) Activation of Epac stimulates integrin-dependent homing of progenitor cells. Blood 111(5):2640–2646PubMedCrossRef Carmona G, Chavakis E, Koehl U, Zeiher AM, Dimmeler S (2008) Activation of Epac stimulates integrin-dependent homing of progenitor cells. Blood 111(5):2640–2646PubMedCrossRef
26.
go back to reference Mias C, Trouche E, Seguelas M-H, Calcagno F, Dignat-George F, Sabatier F et al (2008) Ex vivo pretreatment with melatonin improves survival, proangiogenic/mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney. Stem Cells (Dayton, Ohio) 26(7):1749–1757CrossRef Mias C, Trouche E, Seguelas M-H, Calcagno F, Dignat-George F, Sabatier F et al (2008) Ex vivo pretreatment with melatonin improves survival, proangiogenic/mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney. Stem Cells (Dayton, Ohio) 26(7):1749–1757CrossRef
27.
go back to reference Goligorsky MS, Yasuda K, Ratliff B (2010) Dysfunctional endothelial progenitor cells in chronic kidney disease. JASN 21(6):911–919PubMedCrossRef Goligorsky MS, Yasuda K, Ratliff B (2010) Dysfunctional endothelial progenitor cells in chronic kidney disease. JASN 21(6):911–919PubMedCrossRef
28.
go back to reference Rehman J, Li J, Orschell CM, March KL (2003) Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107(8):1164–1169PubMedCrossRef Rehman J, Li J, Orschell CM, March KL (2003) Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107(8):1164–1169PubMedCrossRef
29.
go back to reference Burger D, Gutsol A, Carter A, Allan DS, Touyz RM, Burns KD (2012) Human cord blood CD133+ cells exacerbate ischemic acute kidney injury in mice. Nephrol Dial Transpl. Epub 2012/05/09 Burger D, Gutsol A, Carter A, Allan DS, Touyz RM, Burns KD (2012) Human cord blood CD133+ cells exacerbate ischemic acute kidney injury in mice. Nephrol Dial Transpl. Epub 2012/05/09
30.
go back to reference Patschan D, Backhaus R, Elle HJ, Schwarze K, Henze E, Becker JU et al (2013) Angiopoietin-2 modulates eEOC-mediated renoprotection in AKI in a dose-dependent manner. J Nephrol. Epub 2013/03/12 Patschan D, Backhaus R, Elle HJ, Schwarze K, Henze E, Becker JU et al (2013) Angiopoietin-2 modulates eEOC-mediated renoprotection in AKI in a dose-dependent manner. J Nephrol. Epub 2013/03/12
31.
go back to reference Patschan D, Plotkin M, Goligorsky MS (2006) Therapeutic use of stem and endothelial progenitor cells in acute renal injury: ça ira. Curr Opin Pharmacol 6(2):176–183PubMedCrossRef Patschan D, Plotkin M, Goligorsky MS (2006) Therapeutic use of stem and endothelial progenitor cells in acute renal injury: ça ira. Curr Opin Pharmacol 6(2):176–183PubMedCrossRef
32.
go back to reference Pula G, Mayr U, Evans C, Prokopi M, Vara DS, Yin X et al (2009) Proteomics identifies thymidine phosphorylase as a key regulator of the angiogenic potential of colony-forming units and endothelial progenitor cell cultures. Circ Res 104(1):32–40PubMedCrossRef Pula G, Mayr U, Evans C, Prokopi M, Vara DS, Yin X et al (2009) Proteomics identifies thymidine phosphorylase as a key regulator of the angiogenic potential of colony-forming units and endothelial progenitor cell cultures. Circ Res 104(1):32–40PubMedCrossRef
33.
go back to reference Zhou J, Zhang S, Xue J, Avery J, Wu J, Lind SE et al (2012) Activation of peroxisome proliferator-activated receptor alpha (PPARalpha) suppresses hypoxia-inducible factor-1alpha (HIF-1alpha) signaling in cancer cells. J Biol Chem. Epub 2012/08/31 Zhou J, Zhang S, Xue J, Avery J, Wu J, Lind SE et al (2012) Activation of peroxisome proliferator-activated receptor alpha (PPARalpha) suppresses hypoxia-inducible factor-1alpha (HIF-1alpha) signaling in cancer cells. J Biol Chem. Epub 2012/08/31
34.
go back to reference Wilson JL, Duan R, El-Marakby A, Alhashim A, Lee DL (2012) Peroxisome proliferator activated receptor-alpha agonist slows the progression of hypertension, attenuates plasma interleukin-6 levels and renal inflammatory markers in angiotensin II infused mice. PPAR Res 2012:645969PubMedCentralPubMedCrossRef Wilson JL, Duan R, El-Marakby A, Alhashim A, Lee DL (2012) Peroxisome proliferator activated receptor-alpha agonist slows the progression of hypertension, attenuates plasma interleukin-6 levels and renal inflammatory markers in angiotensin II infused mice. PPAR Res 2012:645969PubMedCentralPubMedCrossRef
35.
go back to reference Lee DL, Wilson JL, Duan R, Hudson T, El-Marakby A (2011) Peroxisome proliferator-activated receptor-alpha activation decreases mean arterial pressure, plasma interleukin-6, and COX-2 while increasing renal CYP4A expression in an acute model of DOCA-salt hypertension. PPAR Res 2011:502631PubMedCentralPubMedCrossRef Lee DL, Wilson JL, Duan R, Hudson T, El-Marakby A (2011) Peroxisome proliferator-activated receptor-alpha activation decreases mean arterial pressure, plasma interleukin-6, and COX-2 while increasing renal CYP4A expression in an acute model of DOCA-salt hypertension. PPAR Res 2011:502631PubMedCentralPubMedCrossRef
36.
go back to reference Zhou Y, Kong X, Zhao P, Yang H, Chen L, Miao J et al (2011) Peroxisome proliferator-activated receptor-alpha is renoprotective in doxorubicin-induced glomerular injury. Kidney Int 79(12):1302–1311PubMedCrossRef Zhou Y, Kong X, Zhao P, Yang H, Chen L, Miao J et al (2011) Peroxisome proliferator-activated receptor-alpha is renoprotective in doxorubicin-induced glomerular injury. Kidney Int 79(12):1302–1311PubMedCrossRef
37.
go back to reference Chung HW, Lim JH, Kim MY, Shin SJ, Chung S, Choi BS et al (2012) High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARalpha-FoxO3a-PGC-1alpha pathway. Nephrol Dial Transpl 27(6):2213–2225CrossRef Chung HW, Lim JH, Kim MY, Shin SJ, Chung S, Choi BS et al (2012) High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARalpha-FoxO3a-PGC-1alpha pathway. Nephrol Dial Transpl 27(6):2213–2225CrossRef
38.
go back to reference Maggiora M, Oraldi M, Muzio G, Canuto RA (2010) Involvement of PPARalpha and PPARgamma in apoptosis and proliferation of human hepatocarcinoma HepG2 cells. Cell Biochem Funct 28(7):571–577PubMedCrossRef Maggiora M, Oraldi M, Muzio G, Canuto RA (2010) Involvement of PPARalpha and PPARgamma in apoptosis and proliferation of human hepatocarcinoma HepG2 cells. Cell Biochem Funct 28(7):571–577PubMedCrossRef
Metadata
Title
Fibrate treatment of eEOCs in murine AKI
Authors
Daniel Patschan
Katrin Schwarze
Elvira Henze
Susann Patschan
Roman Scheidemann
Gerhard Anton Müller
Publication date
01-02-2014
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 1/2014
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-013-0027-y

Other articles of this Issue 1/2014

Journal of Nephrology 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine